Gilead Sciences Inc
GILD117.860USD
+2.610+2.26%
Fechamento 09/11, 16:00（ET）Cotações atrasadas em 15 min
146.38BValor de mercado
23.19P/L TTM
Mais detalhes de Gilead Sciences Inc Empresa
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.
Informações da empresa
Código da empresaGILD
Nome da EmpresaGilead Sciences Inc
Data de listagemJan 22, 1992
CEOMr. Daniel P. O'Day
Número de funcionários17600
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 22
Endereço333 Lakeside Dr
CidadeFOSTER CITY
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94404-1147
Telefone16505743000
Sitehttps://www.gilead.com/
Código da empresaGILD
Data de listagemJan 22, 1992
CEOMr. Daniel P. O'Day
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
86.94K
-3.34%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
25.70K
+23.67%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Ms. Diane Wilfong
Ms. Diane Wilfong
Interim Controller and Principal Accounting Officer
Interim Controller and Principal Accounting Officer
--
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Dr. Ted W. Love, M.D.
Dr. Ted W. Love, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
86.94K
-3.34%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
25.70K
+23.67%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Ms. Diane Wilfong
Ms. Diane Wilfong
Interim Controller and Principal Accounting Officer
Interim Controller and Principal Accounting Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Por EmpresaUSD
Nome
Receita
Proporção
Biktarvy
3.15B
47.25%
Descovy
586.00M
8.79%
Yescarta
386.00M
5.79%
Genvoya
364.00M
5.46%
Sofosbuvir/Velpatasvir
345.00M
5.17%
Outro
1.84B
27.54%
Por RegiãoUSD
Nome
Receita
Proporção
United States
4.47B
67.02%
Europe
1.06B
15.94%
Other Locations
829.00M
12.43%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Biktarvy
3.15B
47.25%
Descovy
586.00M
8.79%
Yescarta
386.00M
5.79%
Genvoya
364.00M
5.46%
Sofosbuvir/Velpatasvir
345.00M
5.17%
Outro
1.84B
27.54%
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.57%
BlackRock Institutional Trust Company, N.A.
5.71%
State Street Global Advisors (US)
4.77%
Fidelity Management & Research Company LLC
4.33%
Capital World Investors
3.73%
Outro
71.89%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.57%
BlackRock Institutional Trust Company, N.A.
5.71%
State Street Global Advisors (US)
4.77%
Fidelity Management & Research Company LLC
4.33%
Capital World Investors
3.73%
Outro
71.89%
Tipos de investidores
Investidores
Proporção
Investment Advisor
52.75%
Investment Advisor/Hedge Fund
26.40%
Pension Fund
2.96%
Research Firm
2.61%
Hedge Fund
2.24%
Bank and Trust
1.83%
Sovereign Wealth Fund
1.71%
Insurance Company
0.13%
Venture Capital
0.10%
Outro
9.26%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
3388
1.12B
90.01%
-12.02M
2025Q1
3442
1.12B
90.14%
-10.49M
2024Q4
3313
1.12B
90.13%
+4.63M
2024Q3
3207
1.10B
88.48%
-11.56M
2024Q2
3188
1.10B
88.24%
-14.37M
2024Q1
3196
1.10B
88.13%
-22.04M
2023Q4
3252
1.11B
88.75%
-8.79M
2023Q3
3190
1.10B
88.14%
-23.58M
2023Q2
3196
1.10B
88.02%
-11.22M
2023Q1
3195
1.09B
87.26%
-11.17M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
116.91M
9.4%
+1.94M
+1.69%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
70.66M
5.68%
-3.80M
-5.11%
Mar 31, 2025
State Street Global Advisors (US)
59.52M
4.79%
-858.08K
-1.42%
Mar 31, 2025
Fidelity Management & Research Company LLC
51.21M
4.12%
+16.57M
+47.83%
Mar 31, 2025
Capital World Investors
53.55M
4.3%
-18.16M
-25.32%
Mar 31, 2025
Wellington Management Company, LLP
27.36M
2.2%
-8.30M
-23.28%
Mar 31, 2025
Capital Research Global Investors
54.61M
4.39%
-3.34M
-5.76%
Mar 31, 2025
Dodge & Cox
32.69M
2.63%
-252.93K
-0.77%
Mar 31, 2025
Geode Capital Management, L.L.C.
28.48M
2.29%
+190.23K
+0.67%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
25.70M
2.07%
-130.67K
-0.51%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de set
Atualizado em: ter, 2 de set
Nome
Proporção
VanEck Biotech ETF
13.21%
iShares Biotechnology ETF
6.83%
Invesco Biotechnology & Genome ETF
5.14%
Invesco Pharmaceuticals ETF
5.03%
Simplify Health Care ETF
4.44%
TBG Dividend Focus ETF
3.88%
First Trust NYSE Arca Biotechnology Index Fund
3.52%
iShares U.S. Healthcare ETF
2.85%
Health Care Select Sector SPDR Fund
2.79%
WisdomTree U.S. High Dividend Fund
2.74%
Ver Mais
VanEck Biotech ETF
Proporção13.21%
iShares Biotechnology ETF
Proporção6.83%
Invesco Biotechnology & Genome ETF
Proporção5.14%
Invesco Pharmaceuticals ETF
Proporção5.03%
Simplify Health Care ETF
Proporção4.44%
TBG Dividend Focus ETF
Proporção3.88%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.52%
iShares U.S. Healthcare ETF
Proporção2.85%
Health Care Select Sector SPDR Fund
Proporção2.79%
WisdomTree U.S. High Dividend Fund
Proporção2.74%
Dividendo
Um total de
18.49B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Feb 11, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025
Mar 14, 2025
Mar 28, 2025
Mar 14, 2025
Nov 12, 2024
GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024
Dec 13, 2024
Dec 30, 2024
Dec 13, 2024
Aug 13, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024
Sep 13, 2024
Sep 27, 2024
Sep 13, 2024
Apr 26, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024
Jun 14, 2024
Jun 27, 2024
Jun 14, 2024
Feb 06, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Mar 28, 2024
Mar 14, 2024
Nov 08, 2023
GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023
Dec 15, 2023
Dec 28, 2023
Dec 14, 2023
Aug 07, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Sep 28, 2023
Sep 14, 2023
Apr 28, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jun 29, 2023
Jun 14, 2023
Feb 02, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Mar 30, 2023
Mar 14, 2023
Oct 27, 2022
GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022
Dec 15, 2022
Dec 29, 2022
Dec 14, 2022
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
